Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGM - Delayed Quote USD

Aspire Biopharma Holdings, Inc. (ASBP)

0.5210
-0.0002
(-0.04%)
At close: April 23 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ASBP

Recent News: ASBP

View More
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
GlobeNewswire 7 days ago
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
ACCESS Newswire 9 days ago
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
ACCESS Newswire 12 days ago
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ACCESS Newswire 14 days ago
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
ACCESS Newswire last month
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
ACCESS Newswire last month
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
Newsfile last month
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
ACCESS Newswire last month
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
ACCESS Newswire last month
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
ACCESS Newswire 2 months ago
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
ACCESS Newswire 2 months ago
View More

Related Tickers

ARTL Artelo Biosciences, Inc.
1.0300
-11.21%
 
TNFA TNF Pharmaceuticals, Inc.
0.1881
+5.73%
 
TCRT Alaunos Therapeutics, Inc.
2.4600
+2.50%
 
HEPA Hepion Pharmaceuticals, Inc.
0.2840
+1.39%
 
QTTB Q32 Bio Inc.
1.9000
-0.52%
 
AVTE Aerovate Therapeutics, Inc.
2.7400
-0.72%
 
AEON AEON Biopharma, Inc.
0.4399
+8.62%
 
CALA Calithera Biosciences, Inc.
0.0050
0.00%
 
IPHA Innate Pharma S.A.
1.9955
+5.03%
 
OKUR OnKure Therapeutics, Inc.
2.7600
+6.15%